PHIO PHARMACEUTICALS CORP. — Income Charts
52 quarters of history · ending 2024-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue
$217K
R&D↓-2.2% -$22K
$985K
D&A↓-100.0% -$10K
$0
Operating Income↑+42.7% +$1M
$-2M
EBITDA↓-100.0% -$10K
$0
Interest Expense
$-53K
Other Income/Expense
$-1K
Pretax Income↑+39.7% +$983K
$-1M
Tax Provision
$0
Net Income↑+45.2% +$1M
$-2M
Operating Margin↓-484.3pts
-10219.0%
Net Margin↓-355.7pts
-10090.5%
Effective Tax Rate↑+0.0pts
0.0%
ETR (Continuing Operations)↑+0.0pts
0.0%
ETR Federal Statutory↑+0.0pts
21.0%
ETR State + Local (pp)↑+4.7pts
10.6%
Operating Lease Cost↑+18.2% +$6K
$39K
Revenue YoY Variation↓-91.3pts
-100.0%
Income YoY Variation↑+20.5pts
42.7%
Revenue QoQ Variation↓-252.2pts
-100.0%
Income QoQ Variation↑+25.9pts
16.9%